The selection of specific gene pairs such as EGFR–ALK, EGFR–ROS1, and EML4–ROS1 was informed by their recognized role as oncogenic drivers in NSCLC and their clinical relevance in targeted therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.